 The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohns Disease CD and to measure the effects of treatment on patient general well-being, health-related quality of life QoL, fistula healing, CD-related extra-intestinal manifestations, work performance, and overall activity. 